653
edits
Difference between revisions of "Apocrine carcinoma of the breast"
Jump to navigation
Jump to search
Apocrine carcinoma of the breast (view source)
Revision as of 11:58, 1 April 2015
, 11:58, 1 April 2015→IHC
(→IHC) |
(→IHC) |
||
| Line 66: | Line 66: | ||
*ER -ve. | *ER -ve. | ||
*PR -ve. | *PR -ve. | ||
*often Her2 -ve | *often Her2 +ve but can be Her2 -ve | ||
Notes | Notes | ||
*Salivary gland carcinoma and cutaneous adnexal tumors can show a similar IHC profile. | *Salivary gland carcinoma and cutaneous adnexal tumors can show a similar IHC profile. | ||
*Apocrine carcioma can be a non-basal type 'triple negative carcinoma' | *Apocrine carcioma can be a non-basal type 'triple negative carcinoma' <ref>{{Cite journal | last1 = Tsutsumi | first1 = Y. | title = Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma. | journal = Jpn J Clin Oncol | volume = 42 | issue = 5 | pages = 375-86 | month = May | year = 2012 | doi = 10.1093/jjco/hys034 | PMID = 22450930 }}</ref>. | ||
**May show different behaviour to other types of triple negative carcinoma | **May show different behaviour to other types of triple negative carcinoma | ||
**May respond to treatments targeting the androgen receptor<ref>{{Cite journal | last1 = Safarpour | first1 = D. | last2 = Tavassoli | first2 = FA. | title = A Targetable Androgen Receptor-Positive Breast Cancer Subtype Hidden Among the Triple-Negative Cancers. | journal = Arch Pathol Lab Med | volume = | issue = | pages = | month = Oct | year = 2014 | doi = 10.5858/arpa.2014-0122-RA | PMID = 25310144 }} | **May respond to treatments targeting the androgen receptor<ref>{{Cite journal | last1 = Safarpour | first1 = D. | last2 = Tavassoli | first2 = FA. | title = A Targetable Androgen Receptor-Positive Breast Cancer Subtype Hidden Among the Triple-Negative Cancers. | journal = Arch Pathol Lab Med | volume = | issue = | pages = | month = Oct | year = 2014 | doi = 10.5858/arpa.2014-0122-RA | PMID = 25310144 }} | ||
</ref> | </ref> | ||
*Be careful when reading the literature in this area - is the author discussing 'molecular apocrine' (ER -ve, AR +ve) or 'morphologic apocrine' carcinoma. | |||
*Many ductal carcinomas, NOS will show AR positivity but are often ER +ve. | |||
==See also== | ==See also== | ||